GT Biopharma, Inc. (NASDAQ:GTBP) Short Interest Update

GT Biopharma, Inc. (NASDAQ:GTBP) was the recipient of a significant growth in short interest during the month of August. As of August 15th, there was short interest totalling 19,300 shares, a growth of 14.9% from the July 31st total of 16,800 shares. Approximately 0.9% of the company’s shares are short sold. Based on an average trading volume of 42,500 shares, the short-interest ratio is currently 0.5 days.

GT Biopharma Trading Down 1.5 %

GTBP opened at $2.15 on Friday. The business’s 50 day moving average price is $2.56 and its 200 day moving average price is $3.42. GT Biopharma has a one year low of $2.07 and a one year high of $10.66.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in GT Biopharma stock. DekaBank Deutsche Girozentrale acquired a new position in shares of GT Biopharma, Inc. (NASDAQ:GTBP) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 1,093,645 shares of the company’s stock, valued at approximately $47,449,000. DekaBank Deutsche Girozentrale owned 77.02% of GT Biopharma at the end of the most recent quarter. 8.15% of the stock is owned by institutional investors.

About GT Biopharma

GT Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies.